Annovis Bio (ANVS) Competitors $4.37 -0.03 (-0.68%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ANVS vs. BNTC, FHTX, ELDN, URGN, RZLT, AVIR, LRMR, CMRX, ATYR, and MRSNShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Benitec Biopharma (BNTC), Foghorn Therapeutics (FHTX), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), Larimar Therapeutics (LRMR), Chimerix (CMRX), Atyr PHARMA (ATYR), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Benitec Biopharma Foghorn Therapeutics Eledon Pharmaceuticals UroGen Pharma Rezolute Atea Pharmaceuticals Larimar Therapeutics Chimerix Atyr PHARMA Mersana Therapeutics Annovis Bio (NYSE:ANVS) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment. Does the media refer more to ANVS or BNTC? In the previous week, Benitec Biopharma had 9 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for Benitec Biopharma and 4 mentions for Annovis Bio. Benitec Biopharma's average media sentiment score of 0.70 beat Annovis Bio's score of 0.57 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ANVS or BNTC? Annovis Bio has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Do insiders & institutionals believe in ANVS or BNTC? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 32.3% of Annovis Bio shares are owned by insiders. Comparatively, 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer ANVS or BNTC? Benitec Biopharma received 164 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 96.77% of users gave Annovis Bio an outperform vote while only 65.32% of users gave Benitec Biopharma an outperform vote. CompanyUnderperformOutperformAnnovis BioOutperform Votes3096.77% Underperform Votes13.23%Benitec BiopharmaOutperform Votes19465.32% Underperform Votes10334.68% Which has stronger valuation and earnings, ANVS or BNTC? Benitec Biopharma has higher revenue and earnings than Annovis Bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$56.20M-$4.46-0.98Benitec Biopharma$80K3,311.18-$21.75M-$2.84-4.02 Is ANVS or BNTC more profitable? Benitec Biopharma's return on equity of -60.28% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -876.22% -311.00% Benitec Biopharma N/A -60.28%-53.02% Do analysts rate ANVS or BNTC? Annovis Bio presently has a consensus target price of $32.17, indicating a potential upside of 636.08%. Benitec Biopharma has a consensus target price of $24.43, indicating a potential upside of 114.10%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummaryBenitec Biopharma beats Annovis Bio on 12 of the 17 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$60.29M$6.58B$5.13B$19.18BDividend YieldN/A2.99%5.08%3.61%P/E Ratio-0.9810.4689.5841.30Price / SalesN/A195.791,116.1217.60Price / CashN/A57.1642.8221.28Price / Book-5.995.094.775.32Net Income-$56.20M$151.83M$120.15M$989.88M7 Day Performance-17.70%-2.13%-1.92%-3.54%1 Month Performance-35.64%-3.10%11.47%-3.68%1 Year Performance-61.36%11.54%30.52%12.14% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.3136 of 5 stars$4.37-0.7%$32.17+636.1%-59.3%$60.29MN/A-0.983News CoverageBNTCBenitec Biopharma3.6885 of 5 stars$12.13+3.1%$24.43+101.4%+277.8%$281.66M$80,000.000.0020Analyst RevisionFHTXFoghorn Therapeutics2.8809 of 5 stars$5.01-5.5%$16.00+219.4%-14.0%$278.52M$25.52M-2.76120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeELDNEledon Pharmaceuticals2.9252 of 5 stars$4.53+3.4%$16.00+253.2%+196.6%$270.62MN/A-2.3310Positive NewsURGNUroGen Pharma3.8754 of 5 stars$11.47+1.1%$43.70+281.0%-28.4%$268.97M$82.71M-3.60200RZLTRezolute3.1803 of 5 stars$4.64+1.1%$24.13+419.9%+387.8%$268.86MN/A-3.6140AVIRAtea Pharmaceuticals3.0689 of 5 stars$3.16+7.8%$6.88+117.7%+5.6%$266.90M$351.37M-1.5370High Trading VolumeLRMRLarimar Therapeutics1.5624 of 5 stars$4.16-32.6%$20.43+391.1%+4.4%$265.45MN/A-3.5630Analyst RevisionNews CoveragePositive NewsGap DownHigh Trading VolumeCMRXChimerix4.3425 of 5 stars$2.93-0.7%$8.50+190.1%+218.1%$263.52M$320,000.00-3.1472ATYRAtyr PHARMA2.4771 of 5 stars$3.11+1.6%$19.25+519.0%N/A$261.06M$235,000.00-3.2656News CoverageMRSNMersana Therapeutics4.3105 of 5 stars$2.09-2.8%$6.00+187.1%-16.2%$258.18M$36.85M-3.52150Positive News Related Companies and Tools Related Companies Benitec Biopharma Competitors Foghorn Therapeutics Competitors Eledon Pharmaceuticals Competitors UroGen Pharma Competitors Rezolute Competitors Atea Pharmaceuticals Competitors Larimar Therapeutics Competitors Chimerix Competitors Atyr PHARMA Competitors Mersana Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANVS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts